Overview

Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study

Status:
Completed
Trial end date:
2017-03-29
Target enrollment:
Participant gender:
Summary
This is a retrospective, multicenter, descriptive analysis of patients with a diagnosis of chronic myeloid leukemia, treated with dasatinib for at least 45 days. The study will include 100 patients treated in different public centers in the Mexican Republic.
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Dasatinib